Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
- PMID: 29221990
- DOI: 10.1016/j.jbior.2017.11.007
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer
Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, embolization, radiation, chemotherapy, immunotherapy and use of other more targeted drugs. In this review, we describe the cellular and molecular effects of current chemotherapy drugs such as gemcitabine, FOLFIRINOX (5-fluorouracil [5-FU], oxaliplatin, irinotecan, and leucovorin) and ABRAXANE (nab-Paclitaxel), which have shown a survival benefit, although modest, for pancreatic cancer patients. Nevertheless, gemcitabine remains the standard first-line option for advanced-stage pancreatic cancer patients and, as resistance to the drug has attracted an increasing scientific interest, we deliberate on the main intracellular processes and proteins vital in acquired chemoresistance to gemcitabine. Lastly, our review examines various microenvironmental factors capable of instigating PDAC to develop resistance to chemotherapeutic drugs.
Keywords: Chemoresistance; Gemcitabine; Pancreatic cancer; Tumour microenvironment.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2021 Feb;6(2):128-138. doi: 10.1016/S2468-1253(20)30330-7. Epub 2020 Dec 16. Lancet Gastroenterol Hepatol. 2021. PMID: 33338442 Clinical Trial.
-
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.Digestion. 2016;94(1):44-9. doi: 10.1159/000447739. Epub 2016 Jul 21. Digestion. 2016. PMID: 27438590 Review.
-
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.Crit Rev Oncog. 2019;24(2):199-212. doi: 10.1615/CritRevOncog.2019031641. Crit Rev Oncog. 2019. PMID: 31679214 Review.
-
Chemoresistance in Pancreatic Cancer.Int J Mol Sci. 2019 Sep 11;20(18):4504. doi: 10.3390/ijms20184504. Int J Mol Sci. 2019. PMID: 31514451 Free PMC article. Review.
-
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.Eur J Cancer. 2022 Oct;174:102-112. doi: 10.1016/j.ejca.2022.06.042. Epub 2022 Aug 18. Eur J Cancer. 2022. PMID: 35988408
Cited by
-
Tephrosin Suppresses the Chemoresistance of Paclitaxel-Resistant Ovarian Cancer via Inhibition of FGFR1 Signaling Pathway.Biomedicines. 2023 Nov 27;11(12):3155. doi: 10.3390/biomedicines11123155. Biomedicines. 2023. PMID: 38137377 Free PMC article.
-
Super-enhancers modulate interleukin-6 expression and function in cancers.Transl Cancer Res. 2020 Sep;9(9):5555-5565. doi: 10.21037/tcr-19-2825. Transl Cancer Res. 2020. PMID: 35117919 Free PMC article.
-
A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.J Transl Med. 2020 Jun 12;18(1):234. doi: 10.1186/s12967-020-02407-8. J Transl Med. 2020. PMID: 32532289 Free PMC article.
-
Serine, glycine and one‑carbon metabolism in cancer (Review).Int J Oncol. 2021 Feb;58(2):158-170. doi: 10.3892/ijo.2020.5158. Epub 2020 Dec 11. Int J Oncol. 2021. PMID: 33491748 Free PMC article. Review.
-
Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway.Cancers (Basel). 2025 Feb 3;17(3):511. doi: 10.3390/cancers17030511. Cancers (Basel). 2025. PMID: 39941877 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical